Former Departmental CSO of Eli Lilly Joins Envisagenics Board of DirectorsJuly 16, 2024
Envisagenics Raises Series B to Fuel AI-Enabled Novel Therapeutic Pipeline and Expand Depth and Breadth of Commercial OfferingsJune 4, 2024
Results from evaluation of the company’s SpliceCore® AI/ML platform in Triple Negative Breast Cancer published in Molecular Systems BiologyApril 25, 2024
Envisagenics, Cancer Research Horizons, and Queen Mary University of London Announce Strategic Collaboration AgreementDecember 13, 2022
Envisagenics Announces Research Collaboration with Bristol Myers SquibbNovember 29, 2022
Oxford Global – Biologics Analysis – Insight Article – The Black Box Effect – How Can AI and ML Provide Transparent Insights for Drug Discovery?August 30, 2022
Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy DevelopmentAugust 2, 2022
Alliance for Artificial Intelligence in Healthcare Elects New Board Leadership for 2022March 2, 2022
Envisagenics Raises Series A Financing to Scale Its AI-powered RNA Splicing Drug Discovery PlatformSeptember 29, 2021
Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing ResearchMay 13, 2021
Envisagenics Announces Research Program with the Lung Cancer Initiative at Johnson & JohnsonJanuary 21, 2020
Envisagenics wins another SBIR grant from the National Cancer Institute to enhance their AI/ML platform for Immunotherapy developmentJanuary 13, 2020
National Institutes of Health Awards Envisagenics with $1.5M Phase II SBIR GrantMay 22, 2018
Envisagenics Named North American Winner of Innovate.AI CompetitionMay 1, 2018
Envisagenics Closes $2.35M Seed Round and Launches SpliceCore™ PlatformNovember 28, 2017
Innovation in Health Symposiums, Promote Holistic Health and Cutting-Edge Solutions Super Bowl WeekEIN Presswire - January 30, 2025
2023 forecast: An ‘inflection point’ for biopharma, fueled by a flood of AI and machine learning productsFierece Pharma - December 21, 2022
M12 and VC partners award $3.5 million to most innovative companies harnessing the power of artificial intelligenceWebWire Press Release - May 1, 2018
Envisagenics closes $2.35M seed round and launches SpliceCore Platform for identifying RNA targets from splicing errorsRNA-Seq Blog - November 29, 2017
Thiel’s Breakout Labs backs EnvisagenicsNew York Business Journal - April 17, 2017
These New York women thrive in male-dominated industriesNew York Post - February 26, 2017
This program gives hot startups free office space in New York City for a year — meet this year’s winnersBusiness Insider - July 12, 2016
2015 Innovator of the Year AwardsInnovate Long Island - October 21, 2015
Envisagenics lands $225K NIH awardInnovate Long Island - August 13, 2015
LI biotech startup receives $225,000 grant from NIHNewsDay - August 13, 2015
Startup Envisagenics Nabs NIH Grant to Develop Alternative Splicing Analysis TechGenomeWeb - August 13, 2015
Accelerate LI, Eyeing New Seed Fund, Debuts Ninth Grad: EnvisagenicsXconomy - July 29, 2015
Accelerate Long Island and the Long Island Emerging Technologies Fund Announce $100,000 Investment in EnvisagenicsAccelerate Long Island - July 29, 2015
Tech startup Envisagenics receives $100,000 in fundingNewsday - July 28, 2015
Envisagenics Gets $100K in Seed FundingInnovate Long Island - July 27, 2025
Helping Big Pharma Master Big DataInnovate Long Island - July 16, 2015